Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260349 | 0.88 | ZDHHC7 (0.44) | GPR84FFAR1ZDHHC7CPB2MAPT | |
| SCHEMBL2803737 | 0.88 | ZDHHC7 (0.44) | GPR84FFAR1ZDHHC7CPB2MAPT | |
| SCHEMBL4119282 | 0.86 | ZDHHC7 (0.42) | GPR84FFAR1ZDHHC7CPB2MAPT | |
| SCHEMBL7070785 | 0.84 | ZDHHC7 (0.50) | GPR84FFAR1ZDHHC7FFAR4CPB2 | |
| SCHEMBL19690704 | 0.84 | ZDHHC7 (0.50) | GPR84FFAR1ZDHHC7FFAR4CPB2 | |
| Acetic Acid SCHEMBL9301447 | 0.83 | GPR84 (0.42) | GPR84FFAR1ZDHHC7FFAR4CPB2 | |
| SCHEMBL13269368 | 0.82 | ZDHHC7 (0.47) | GPR84FFAR1ZDHHC7CPB2MAPT | |
| SCHEMBL29186605 | 0.81 | GPR84 (0.46) | GPR84FFAR1ZDHHC7FFAR4MAPT | |
| SCHEMBL2249063 | 0.81 | FAAH (0.46) | GPR84FFAR1ZDHHC7FFAR4MAPT | |
| SCHEMBL21436424 | 0.81 | FAAH (0.46) | GPR84FFAR1ZDHHC7FFAR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | GPR84 4114/4885FFAR1 3626/4885ZDHHC7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.